Similar Papers

Paper Title
Journal
Date
Author
Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study.
Barbara Averill ... Wencai Ma
Cancer | VOL. 130
Barbara Averill, et. al.Barbara Averill ... Wencai Ma
20 Nov 2023
Newer monoclonal antibodies for hematological malignancies
Jorge Castillo ... Peter Quesenberry
Experimental hematology | VOL. 36
Jorge Castillo, et. al.Jorge Castillo ... Peter Quesenberry
17 Jun 2008
Quantification of MRD in rituximab plus CHOP (R-CHOP) therapy in follicular lymphoma (FL): Results of a randomized trial comparing the concurrent and sequential administrations
T Kinoshita ... J Enami
Journal of Clinical Oncology | VOL. 22
T Kinoshita, et. al.T Kinoshita ... J Enami
15 Jul 2004
Therapy with Ibritumomab Tiuxetan (Zevalin®) in Patients with Previously Untreated and Relapsed Low Grade Follicular Lymphoma: The Mayo Clinic Florida Experience, 2000-2016
Aixa Elena Soyano ... Jennifer Peterson
Blood | VOL. 128
Aixa Elena Soyano, et. al.Aixa Elena Soyano ... Jennifer Peterson
02 Dec 2016
View more papers

More From: Clinical Lymphoma, Myeloma and Leukemia

Paper Title
Journal
Date
Author
SOHO State of the Art Updates and Next Questions | Venetoclax + Obinutuzumab Therapy in Chronic Lymphocytic Leukemia
Andrew H Lipsky ... Nicole Lamanna
Clinical Lymphoma, Myeloma and Leukemia | VOL. -
Andrew H Lipsky, et. al.Andrew H Lipsky ... Nicole Lamanna
01 Dec 2024
Table of Contents
-
Clinical Lymphoma, Myeloma and Leukemia | VOL. 24
--
01 Dec 2024
A phase I study of romidepsin in combination with gemcitabine, oxaliplatin, and dexamethasone in patients with relapsed or refractory aggressive lymphomas enriched for T-cell lymphomas.
Nicole Foley ... Neha Mehta-Shah
Clinical Lymphoma, Myeloma and Leukemia | VOL. -
Nicole Foley, et. al.Nicole Foley ... Neha Mehta-Shah
01 Dec 2024
Editorial Board
-
Clinical Lymphoma, Myeloma and Leukemia | VOL. 24
--
01 Dec 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.